Loading...
Loading...
India's rivaroxaban imports from GERMANY total $34.1B across 129 shipments from 15 foreign suppliers. BAYER AG leads with $34.1B in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include BAYER ZYDUS PHARMA PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for rivaroxaban — a diversified sourcing base with multiple active suppliers from GERMANY.

BAYER AG is the leading Rivaroxaban supplier from GERMANY to India, with import value of $34.1B across 43 shipments. The top 5 suppliers — BAYER AG, PRIVAPOSERVICES GMBH, ILAPO, SAVI CLINICALS FZ LLC, ESPEE Pharma (UK) LTD — collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) · Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | BAYER AG | $34.1B | 43 | 100.0% |
| 2 | PRIVAPOSERVICES GMBH | $30.9K | 8 | 0.0% |
| 3 | ILAPO | $15.0K | 9 | 0.0% |
| 4 | SAVI CLINICALS FZ LLC | $13.4K | 4 | 0.0% |
| 5 | ESPEE Pharma (UK) LTD | $13.2K | 2 | 0.0% |
| 6 | ILAPO-INTERN LUDWIGS-ARZENIMITTELGMBH&CO.KG | $10.5K | 6 | 0.0% |
| 7 | PHARMACEUTICAL BUYERS, INC | $8.2K | 2 | 0.0% |
| 8 | ILAPO-INTERNATIONALE LUDWIGS-ARZENIMITTELGMBH CO K | $7.5K | 2 | 0.0% |
| 9 | ILAPO-INTERNATIONALE LUDWIGS- | $6.9K | 1 | 0.0% |
| 10 | NEWLIFE BIOPHARMA LIMITED | $6.9K | 2 | 0.0% |
| 11 | Globyz Biopharma Limited | $6.4K | 2 | 0.0% |
| 12 | SIA GP NORD | $6.3K | 5 | 0.0% |
| 13 | M/S. NEW LIFE MEDICALS LLC | $4.5K | 2 | 0.0% |
| 14 | privaposervices GmbH | $4.4K | 4 | 0.0% |
| 15 | IKRIS PHARMA INTERNATIONAL SPRL | $3.8K | 4 | 0.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | BAYER ZYDUS PHARMA PRIVATE LIMITED | $34.1B | 39 | 100.0% |
| 2 | BAYER PHARMACEUTICALS PRIVATE LIMITED | $2.5M | 4 | 0.0% |
| 3 | WATSON PHARMA PRIVATE LIMITED | $34.5K | 14 | 0.0% |
| 4 | HETERO LABS LIMITED | $28.2K | 11 | 0.0% |
| 5 | UNICHEM LABORATORIES LIMITED | $22.0K | 4 | 0.0% |
| 6 | MANKIND PHARMA LIMITED | $18.3K | 8 | 0.0% |
| 7 | AUROBINDO PHARMA LTD | $7.2K | 1 | 0.0% |
| 8 | UMEDICA LABORATORIES PRIVATE LIMITED | $7.2K | 3 | 0.0% |
| 9 | OPTIMUS PHARMA PRIVATE LIMITED | $6.4K | 2 | 0.0% |
| 10 | TORRENT PHARMACEUTICALS LTD | $4.9K | 6 | 0.0% |
| 11 | INDOCO REMEDIES LIMITED | $4.5K | 2 | 0.0% |
| 12 | INVENTIA HEALTHCARE LIMITED | $4.4K | 4 | 0.0% |
| 13 | CENTAUR PHARMACEUTICALS PRIVATE LIMITED | $3.8K | 4 | 0.0% |
| 14 | MICRO LABS LIMITED | $3.6K | 1 | 0.0% |
| 15 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $2.4K | 2 | 0.0% |
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Rivaroxaban suppliers from GERMANY to India include BAYER AG, PRIVAPOSERVICES GMBH, ILAPO. The leading supplier is BAYER AG with import value of $34.1B USD across 43 shipments. India imported Rivaroxaban worth $34.1B USD from GERMANY in total across 129 shipments.
India imported Rivaroxaban worth $34.1B USD from GERMANY across 129 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Rivaroxaban sourced from GERMANY include BAYER ZYDUS PHARMA PRIVATE LIMITED, BAYER PHARMACEUTICALS PRIVATE LIMITED, WATSON PHARMA PRIVATE LIMITED. The largest buyer is BAYER ZYDUS PHARMA PRIVATE LIMITED with $34.1B in imports across 39 shipments.
The total value of Rivaroxaban imports from GERMANY to India is $34.1B USD, across 129 shipments and 15 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
129 Verified Shipments
15 suppliers, 15 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists